The Newsroom

Investigations  /  01.10.2020

Investigation of Nektar Therapeutics

Nektar Therapeutics (NKTR) Accused of Misrepresenting the Viability of its Drug NKTR-214

According to the complaint, Nektar touted to investors that NKTR-214 was a promising new universal cancer treatment drug.  Nektar further asserted that it could improve the drug by adding polyethylene glycol molecules to IL-2, a process known as “pegylating,” to extend the half-life and reduce side effects.  To investors’ surprise, on October 1, 2018, a report published by Plainview LLC claimed that NKTR-214 did not live up to Nektar’s claims and expectations for the drug’s safety and efficacy.  The report revealed that Nektar had withheld 69% of response rates on dosed patients in its PIVOT study “in an unprecedented level of data opacity.”  In addition, the report alleged that pegylation impaired the efficacy of NKTR-214, rendering it “completely useless for treating cancer.”  On this news, Nektar’s stock price fell over 9% over the following two trading sessions to close at $55.33 on October 2, 2018, and continues to decline, closing today at around just $21.50.

Nektar Therapeutics (NKTR) Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can send us a message via the Shareholder Information form below.

Shareholder Information

  • Please Note: Neither the submission to nor the receipt of information by Robbins LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

Please Note: Neither the submission to nor the receipt of information by Robbins LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

How can we help you?

CONTACT US TODAY | 1 800 350 6003 or [email protected]

Tell us your concerns